牛氓的胜利2019-01-27 00:31
如果$中国生物制药(01177)$敢于用‘’多发性骨髓瘤适应症‘’上市销售,明显违反国内知识产权法律,沦为川普的打击对象。$新基制药(CELG)$会让违法的药企赔偿5~10亿元以上。
如果正大天晴试图挑战专利,需要推翻新基制药3个多发性骨髓瘤用途专利,否则一定会涉嫌侵权。
其中,CN103495169...查看全文
啃医药股的熊猫2019-01-26 16:15
【汇众医疗】著名股评人 Jim Cramer 推荐七大投资领域,肿瘤疗法入围
$新$新基制药(CELG)$ $$Loxo Oncology(LOXO)$ $$Tesaro(TSRO)$ CNBC王牌主持人、著名的美国股市评论员吉姆·克莱默(Jim Cramer)表示,2019年七大投资领域分别是:航天航空、5G、癌症治愈、数字化、住房和汽车、零售和中国市...查看全文
淘沙见金2019-01-23 08:03
$新基制药(CELG)$ “Genentech was the company biotech should have kept. Celgene is the company biotech is happy to lose.” 新基这么不招人待见啊网页链接查看全文
医药魔方2019-01-22 09:06
1月18日,Celgene宣布与一家致力于开发免疫系统免受癌症侵袭产品的初创企业Kyn Therapeutics展开合作。
Kyn是由Atlas Venture和OrbiMed投资,总部位于波士顿。Celgene将向Kyn支付8000万美元的首付款以及金额未透露的股权投资,获得两种免疫代谢调节剂的独家权利,Celgene将在Kyn完成Ib期临床试...查看全文
不明真相的艾晨2019-01-20 15:06
Celgene在美东时间周五宣布与两家肿瘤免疫公司 Kyn Therapeutics and Obsidian Therapeutics达成合作协议。$百时美施贵宝(BMY)$ $新基制药(CELG)$
Kyn公司将收到8千万美金首付款,授权两个靶点 AHR(aryl hydrocarbon receptor antagonist), and Kynase(kynurenine-degrading enzyme)的候...查看全文
越炒股越美2019-01-19 18:35
【汇众医疗】新基制药与两家公司建立了战略合作关系,开发免疫肿瘤治疗和细胞疗法
$新基制药(CELG)$ 新基制药与波士顿的 Kyn Therapeutics 达成了开发新型免疫肿瘤疗法的协议,提供了8000万美元的预付款,此外,新基制药还与 Obsidian Therapeutics 合作开发了针对癌症的细胞疗法。 查看全文ht...查看全文
啃医药股的熊猫2019-01-19 14:21
【汇众医疗】新基制药与两家公司建立了战略合作关系,开发免疫肿瘤治疗和细胞疗法
$新$新基制药(CELG)$ #细胞疗法##肿瘤免疫疗法#新基制药与波士顿的 Kyn Therapeutics 达成了开发新型免疫肿瘤疗法的协议,提供了8000万美元的预付款,此外,新基制药还与 Obsidian Therapeutics 合作开发了针对...查看全文
$新基制药(CELG)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-013792 Size: 69 KB 网页链接
$新基制药(CELG)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-013796 Size: 42 KB 网页链接
$新基制药(CELG)$ 15-12B Securities registration termination [Section 12(b)] Accession Number: 0001140361-19-022527 Act: 34 Size: 15 KB 网页链接
$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022225 Act: 33 Size: 20 KB 网页链接
$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022228 Act: 33 Size: 20 KB 网页链接
$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022200 Act: 33 Size: 20 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022201 Act: 33 Size: 39 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022206 Act: 33 Size: 39 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022210 Act: 33 Size: 39 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022217 Act: 33 Size: 39 KB 网页链接